Short Interest in Femasys Inc. (NASDAQ:FEMY) Expands By 18.6%

Femasys Inc. (NASDAQ:FEMY) saw a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 579,900 shares, a growth of 18.6% from the November 15th total of 489,100 shares. Approximately 2.7% of the shares of the company are sold short. Based on an average trading volume of 175,600 shares, the short-interest ratio is currently 3.3 days.

Analyst Ratings Changes

Several brokerages recently commented on FEMY. Chardan Capital decreased their price objective on shares of Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Femasys in a research report on Tuesday, December 3rd.

Institutional Trading of Femasys

Several institutional investors have recently added to or reduced their stakes in the stock. CM Management LLC increased its position in shares of Femasys by 6.3% in the 2nd quarter. CM Management LLC now owns 425,000 shares of the company’s stock worth $484,000 after purchasing an additional 25,000 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Femasys by 9.2% in the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after purchasing an additional 17,473 shares during the last quarter. XTX Topco Ltd grew its stake in Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after buying an additional 18,004 shares during the last quarter. Finally, Aljian Capital Management LLC bought a new position in shares of Femasys during the third quarter worth about $27,000. 65.27% of the stock is owned by institutional investors and hedge funds.

Femasys Stock Performance

FEMY remained flat at $1.19 during trading on Monday. 41,679 shares of the company’s stock traded hands, compared to its average volume of 320,484. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86. The stock has a market capitalization of $27.25 million, a price-to-earnings ratio of -1.47 and a beta of -2.89. The stock’s 50-day moving average is $1.14 and its 200 day moving average is $1.11. Femasys has a 12 month low of $0.73 and a 12 month high of $2.40.

Femasys (NASDAQ:FEMY) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. The company had revenue of $0.55 million during the quarter, compared to analysts’ expectations of $0.40 million. Analysts forecast that Femasys will post -0.84 earnings per share for the current fiscal year.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.